I am a University of Chicago gastroenterologist with interest in inflammatory bowel disease (IBD). Tweets - my own.
Chicago, IL
Joined April 2026
- Tweets56
- Following53
- Followers127
- Likes232
Honestly not surprised by this but it emphasizes that strong recommendations and particularly guidelines should be based on evidence not eminence. Both endoscopy and histology are cross-sectional endpoints bound by time. So they have a "best by" date
Prof Vip Jairath VERDICT—basically treating to endoscopic remission in UC was significantly better than treating to symptomatic remission, but treating to histo remission didn’t add anything significant @vipuljairath @UegWeek #uegweek2026
Michael Chiorean retweeted
In Nashville for ACG? Join us tomorrow evening for IUS Monthly Live! Connect with the @iUSCAN iUSCAN community, experience a live intestinal ultrasound demonstration, enjoy food and drinks.
📅 Tuesday, October 13 | 5:30–8:30 PM
📍 Martin’s Bar-B-Que Joint, 410 4th Ave S
RVSP👇
#Obefazimod (miRNA-124 promoter) showing robust induction efficacy in difficult-to-treat (DTT) #UC with some dose response among ADT-IR patients in phase-2 trial. Maintenance data to be presented @UegWeek next week @bruce_sands1 #ACG26
#Icotrokinra (oral IL-23 inhibitor) effectiveness through wk 76 in #UC patients showing durable benefit with favorable safety profile. >40% ADT-IR in the largest dose group. Phase-3 trial enrolling @ibddocmaria #ACG26
SQ IFX (Zymfentra) initiation may be effective to recapture response in #ulcerativecolitis and #crohnsdisease after drug holiday in LIBERTY trials. Presence of drug antibodies did not seem to have an impact. Substantial pt dropout in ADA+ #DrMarlaDubinsky #ACG26
#Upadacitinib demonstrated meaningful benefit in a RW, difficult to treat ileal #crohnsdisease population, with universally positive endpoints. No evidence that disease location matters with Upa in CD #DrDavidDulaney #ACG26
#Guselkumab leads to improvement in non-passable bowel stenoses in #crohnsdisease patients w inflammation at baseline in GALAXI and GRAVITY (IV and SQ induction). Gene expression markers showed correlation btw inflammation and fibrosis #ACG26 #DrDavidRubin
Dr David Rubin @UChicagoMed receiving a well-deserved Master of @AmCollegeGastro award at #ACGcongress2026
#DavidRubinMD - outstanding lecture on the management of #ulcerativecolitis; goals have evolved to include Functional Remission; focus shifting on the Destination not the Journey; tight monitoring using non-invasive biomarkers; match treatment with disease activity (🔑)
Use #EIM to individualize therapy; limit the use of steroids - one and done good rule of thumb to assess effective mgmt; disease extent irrelevant for severity; act FAST in UC - critical need for speed in severe UC #ACGcongress2026
245
Key messages from @AmCollegeGastro guidelines for #crohnsdisease by @EdwardLoftus2 : No need to fail conventional therapy to start an advanced therapy; No use for 5-ASA in #crohnsdisease; p19 inhibitors (esp Risa and Gus) moving as 1st line for non-complicated CD; GUS also PAF
Given favorable safety signal for p19 inhibitors, okay to default to higher maintenance dose before de-escalation; shift to SQ therapy across biologics for convenience (and potential longevity); UPA becoming Top Dog based on efficacy/speed
Any therapy works best if started early (see PROFILE, SEAVUE) #ACGCongress2026
Outstanding presentations on colorectal #neoplasia screening and surveillance in healthy populations and #IBD at #ACG2026. Important highlights: 1. Individualized surveillance intervals for #IBD based on risk: high (PSC, HGD <5 y) - 1 yr; low (deep remission, no prior) - 5 y;
All others: 3 y. 2. Limited but important indications for random bx (PSC, severe inflammation) - yield remains very low. 3. Increasing role for CSP (#coldsnarepolypectomy) in (<20 mm) polyp management. 4. Quality over quantity in surveillance post-polypectomy,
1
1
49
5. Engage patients in the #colonoscopy prep and tailor based on preference/effectiveness/indication @AasmaShaukatMD @NayantaraCoelho #DrBrianJacobson @AmCollegeGastro
Very important data. Some of these "infants" were 17 yo at the last f/u
Long-Term Infant Outcomes After In Utero Biologic Exposure: Results From the Pregnancy Inflammatory Disease Neonatal Outcomes Registry ovid.com/10.14309/ajg.000000… @AKohli_MD @SunandaKaneMD @MLongMD @drdawnbeaulieu
Packed room this morning at the Chicago-Paris #IBD summit in its 4th year. Building strong partnerships between strong centers across the world to improve care, research and data integration @UChicagoMed #ParisIBDcenter
227
JNJ-4804 - Gol+Gus combo trial superior to monotherapy in patients with refractory #UC across both clinical and endoscopic endpoints with no short-term incremental safety signal. Results suggest synergy > addition #DDW2026 #IBD @ibddocmaria
The absolute world leader in this field, worth paying attention to
@RobertHirten MD, shares compelling insights from his research on using wearable technology to monitor how patients with #IBD respond to biologic therapies. #DDW2026
170